Cargando…

Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations

BACKGROUND: No medical treatment has proven efficacy for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF), and this syndrome has a very high mortality. Based on data indicating humoral autoimmune processes are involved in IPF pathogenesis, we treated AE-IPF patients with an autoantibody...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulkarni, Tejaswini, Valentine, Vincent G., Fei, Fei, Tran-Nguyen, Thi K., Quesada-Arias, Luisa D., Mkorombindo, Takudzwa, Pham, Huy P., Simmons, Sierra C., Dsouza, Kevin G., Luckhardt, Tracy, Duncan, Steven R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610261/ https://www.ncbi.nlm.nih.gov/pubmed/34813613 http://dx.doi.org/10.1371/journal.pone.0260345

Ejemplares similares

Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients
por: Kulkarni, Tejaswini, et al.
Publicado: (2019)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
por: Mkorombindo, Takudzwa, et al.
Publicado: (2019)

IPF-Acute Exacerbations: Advances and Future Perspectives
por: Papiris, Spyros A., et al.
Publicado: (2022)

Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF
por: Mills, Ross, et al.
Publicado: (2019)

Diffuse alveolar hemorrhage complicating acute exacerbation of IPF
por: Murohashi, Kota, et al.
Publicado: (2020)

Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
por: Donahoe, Michael, et al.
Publicado: (2015)

Correction: Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
por: Donahoe, Michael, et al.
Publicado: (2015)

The Air We Breathe: Respiratory Impact of Indoor Air Quality in Chronic Obstructive Pulmonary Disease
por: Mkorombindo, Takudzwa, et al.
Publicado: (2022)

Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation
por: Yamazaki, Ryo, et al.
Publicado: (2021)

Postoperative Acute Exacerbation of IPF after Lung Resection for Primary Lung Cancer
por: Watanabe, Atsushi, et al.
Publicado: (2011)

Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema
por: Zantah, Massa, et al.
Publicado: (2020)

Recurrent Pneumonia? A Case of Availability Bias and Anchoring
por: Rentas, Courtney M, et al.
Publicado: (2020)

Development of the ATAQ-IPF: a tool to assess quality of life in IPF
por: Swigris, Jeffrey J, et al.
Publicado: (2010)

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2019)

Autoantibodies Exacerbate the Severity of MHV-Induced Encephalitis
por: Burrer, Renaud, et al.
Publicado: (2006)

Recommendations on treatment for IPF
por: Behr, Jürgen, et al.
Publicado: (2013)

Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
por: de Andrade, Joao A., et al.
Publicado: (2022)

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
por: Jo, Helen E., et al.
Publicado: (2019)

Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF
por: Tóth, Nóra Melinda, et al.
Publicado: (2023)

HLA-C and KIR permutations influence chronic obstructive pulmonary disease risk
por: Mkorombindo, Takudzwa, et al.
Publicado: (2021)

Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry
por: Tsubouchi, Kazuya, et al.
Publicado: (2023)

Impact of Quality Improvement on Care of Chronic Obstructive Pulmonary Disease Patients in an Internal Medicine Resident Clinic
por: Burkes, Robert M., et al.
Publicado: (2018)

Highlights of HRCT imaging in IPF
por: Sverzellati, N
Publicado: (2013)

IPF - Idiopathic Pulmonary Fibrosis
Publicado: (2019)

The role of neutrophils in the pathogenesis of IPF
por: Jegal, Yangjin
Publicado: (2022)

Supportive care of right ventricular failure due to fat embolism syndrome
por: Schwalbach, Kevin T., et al.
Publicado: (2021)

Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior
por: Khine, Ngu, et al.
Publicado: (2020)

IPF clinical trial design and endpoints
por: Nathan, Steven D., et al.
Publicado: (2014)

Mitochondrial Quality Control in COPD and IPF
por: Hara, Hiromichi, et al.
Publicado: (2018)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
por: Barratt, Shaney L., et al.
Publicado: (2018)

The Role of Immunity and Inflammation in IPF Pathogenesis
por: Butler, Marcus W., et al.
Publicado: (2018)

Senescent Cells in IPF: Locked in Repair?
por: Meiners, Silke, et al.
Publicado: (2020)

IPF in Saudi Arabia: Lessons for all
por: Nathan, Steven D.
Publicado: (2020)

Microbiota and IPF: hidden and detected relationships
por: Fabbrizzi, Alessio, et al.
Publicado: (2021)

Radiological and Physiological Predictors of IPF Mortality
por: Kishaba, Tomoo, et al.
Publicado: (2021)

Moving senolytics closer to the clinic in IPF
por: Kramer, Daniel, et al.
Publicado: (2023)

Transcriptome Analysis Reveals Differential Splicing Events in IPF Lung Tissue
por: Nance, Tracy, et al.
Publicado: (2014)

Management of interstitial lung disease in patients with autoimmune disease-related interstitial lung disease
por: Dsouza, Kevin G., et al.
Publicado: (2023)

Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013)

The Role of Cardiopulmonary Exercise Test in IPF Prognosis
por: Triantafillidou, Christina, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qvs84j55qqecifou2saskt7ta9